person · Reporting owner

Conroy Kevin T

Disclosed activity across 8 companies

Tapewire entity: 14500
SEC CIK: 0001306119

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ABBOTT LABORATORIESABT · Entity 2314	Director	September 30, 2026	October 03, 2026
ALIGN TECHNOLOGY INCALGN · Entity 3488	Director	May 20, 2026	May 22, 2026
Adaptive Biotechnologies CorpADPT · Entity 1126	Director	March 06, 2023	March 09, 2023
American Exceptionalism Acquisition Corp. AAEXA · Entity 5376	Director	September 25, 2025	December 30, 2025
SomaLogic, Inc.SLGCW · Entity 95310	Director	September 01, 2021	September 04, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ABBOTT LABORATORIES

Report date September 30, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Equivalent UnitsSEC Table II · derivative / convertible security	Direct	551	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 318 · Balance 551 F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Filing footnotes · ownership attribution and instrument terms

F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock.

F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

ALIGN TECHNOLOGY INC

Report date May 20, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,553	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Exercise / conversion · Acquired 1,745 · Balance 3,553
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-20 · Exercise / conversion · Disposed 1,745 · Balance 0 F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,836	Reported balance After 2026-05-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-20 · Grant · Acquired 1,836 · Balance 1,836 F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the restricted stock units ("RSUs") granted on May 21, 2025 vested on May 20, 2026 and shares were delivered to the Reporting Person.

F2: 100% of the RSUs granted on May 20, 2026 will become vested on the earlier of (i) May 20, 2027 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date.

Adaptive Biotechnologies Corp

Report date March 06, 2023 · Filed March 09, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	22,968	Reported balance After 2023-03-06 transaction · row 1 1 source row Row 1 · 2023-03-06 · Grant · Acquired 14,775 · Balance 22,968
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2033-03-06	Direct	23,329	Reported balance After 2023-03-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-06 · Grant · Acquired 23,329 · Balance 23,329 F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates.

American Exceptionalism Acquisition Corp. A

Report date September 25, 2025 · Filed December 30, 2025 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2025-09-25 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance Not disclosed F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-289701), under the heading "Description of Securities - Founder Shares," Class B ordinary shares will automatically convert into Class A ordinary shares on or prior to the tenth anniversary of the Issuer's initial business combination, upon the earlier of (A) the Issuer meeting certain share price performance thresholds following the completion of its initial business combination, and (B) subsequent to the completion of its initial business combination, the date on which a change of control occurs, in each case, on a one-for-one basis, subject to adjustment as provided therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-289701), under the heading "Description of Securities - Founder Shares," Class B ordinary shares will automatically convert into Class A ordinary shares on or prior to the tenth anniversary of the Issuer's initial business combination, upon the earlier of (A) the Issuer meeting certain share price performance thresholds following the completion of its initial business combination, and (B) subsequent to the completion of its initial business combination, the date on which a change of control occurs, in each case, on a one-for-one basis, subject to adjustment as provided therein.

SomaLogic, Inc.

Report date September 01, 2021 · Filed September 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	25,000	Reported balance After 2021-09-01 transaction · row 1 1 source row Row 1 · 2021-09-01 · Other · Acquired 25,000 · Balance 25,000 F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.
Warrants to purchase Class A Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-09-01	IndirectBy Conroy Family Foundation, Inc.	166,666	Reported balance After 2021-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-09-01 · Grant · Acquired 166,666 · Balance 166,666 F2: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. The Conroy Family Foundation, Inc. (the "Conroy Foundation") is the record holder of the Class A Common Stock exercisable upon the issuance of warrants reported herein. Mr. Conroy has voting and investment discretion with respect to the Class A Common Stock held of record by the Conroy Foundation. As such, Mr. Conroy may be deemed to have or share beneficial ownership of the securities held directly by the Conroy Foundation. Mr. Conroy disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Class B Common StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-09-01 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F2: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. The Conroy Family Foundation, Inc. (the "Conroy Foundation") is the record holder of the Class A Common Stock exercisable upon the issuance of warrants reported herein. Mr. Conroy has voting and investment discretion with respect to the Class A Common Stock held of record by the Conroy Foundation. As such, Mr. Conroy may be deemed to have or share beneficial ownership of the securities held directly by the Conroy Foundation. Mr. Conroy disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARYA SCIENCES ACQUISITION CORP.

Report date July 01, 2020 · Filed July 07, 2020

Section 16 reporting ended · disclosed 2020-07-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-07-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the merger of ARYA Sciences Acquisition Corp. (the "Issuer") with and into a subsidiary of Immatics N.V. ("IMTX"), and a series of related transactions (collectively, the "Business Combination"), the Class B Ordinary Shares, par value $0.0001 per share, of the Issuer held by the Reporting Person were exchanged for Ordinary Shares, nominal value EURO0.01 per share, of IMTX. Upon consummation of the Business Combination the Reporting Person is no longer subject to the reporting requirements of Section 16 with respect to the Issuer's securities.

EXACT SCIENCES CORP

Report date March 23, 2026 · Filed March 23, 2026

Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2026-03-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-03-23 · Grant · Acquired 119,312 · Balance 1,397,738 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Row 2 · 2026-03-23 · Disposition to issuer · Disposed 1,397,738 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectHeld in 401(k) Plan	Reported balance After 2026-03-23 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-03-23 · Disposition to issuer · Disposed 29,061 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectHeld in Grantor Retained Annuity Trust	Reported balance After 2026-03-23 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-03-23 · Disposition to issuer · Disposed 46,538 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectHeld in Grantor Retained Annuity Trust	Reported balance After 2026-03-23 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-03-23 · Disposition to issuer · Disposed 86,750 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectHeld in Grantor Retained Annuity Trust	Reported balance After 2026-03-23 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2026-03-23 · Disposition to issuer · Disposed 117,427 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.68	Direct	Reported balance After 2026-03-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-03-23 · Disposition to issuer · Disposed 235,388 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F4: These options became exercisable in full on February 23, 2021.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37	Direct	Reported balance After 2026-03-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-03-23 · Disposition to issuer · Disposed 66,047 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F8: These options became exercisable on February 27, 2022.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $92.62	Direct	Reported balance After 2026-03-23 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-03-23 · Disposition to issuer · Disposed 34,110 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F9: These options became exercisable on February 26, 2023.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.18	Direct	Reported balance After 2026-03-23 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-03-23 · Disposition to issuer · Disposed 100,916 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F10: These options became exercisable on February 14, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-03-23 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-03-23 · Disposition to issuer · Disposed 18,143 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F15: These RSUs vest in four equal annual installments beginning on February 28, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-03-23 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-03-23 · Disposition to issuer · Disposed 44,336 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F11: These RSUs vest in four equal annual installments beginning on February 28, 2025.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-03-23 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-03-23 · Disposition to issuer · Disposed 83,360 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding. F12: These RSUs vest in four equal annual installments beginning on February 27, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-03-23 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-03-23 · Disposition to issuer · Disposed 154,829 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F14: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F13: These RSUs vest in four equal annual installments beginning on February 25, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.

F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.

F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.

F4: These options became exercisable in full on February 23, 2021.

F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding

F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

F7: At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.

F8: These options became exercisable on February 27, 2022.

F9: These options became exercisable on February 26, 2023.

F10: These options became exercisable on February 14, 2024.

F11: These RSUs vest in four equal annual installments beginning on February 28, 2025.

F12: These RSUs vest in four equal annual installments beginning on February 27, 2026.

F13: These RSUs vest in four equal annual installments beginning on February 25, 2027.

F14: At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.

F15: These RSUs vest in four equal annual installments beginning on February 28, 2024.

Epizyme, Inc.

Report date August 12, 2022 · Filed August 16, 2022

Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001SEC Table I · non-derivative	Direct	0	Ending reported balance After 2022-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-08-12 · Disposition to issuer · Disposed 53,324 · Balance 8,994 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.

F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 28, 2025 Filed Mar 4, 2025 16:47 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	18,143	$0.00	$0.00	Disclosure SEC source: 0000950170-25-032293 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,133,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 25, 2025 Filed Feb 26, 2025 20:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	13,180	$0.00	$0.00	Disclosure SEC source: 0000950170-25-028163 · ownership.xml · derivative · entry 11 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,181 Underlying: Common Stock · 13,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 25, 2022 that vests in four equal annual installments from the grant date. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 25, 2022 that vests in four equal annual installments from the grant date. Read SEC document
February 25, 2025 Filed Feb 26, 2025 20:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Tax withholdingCommon Stock	6,195	$51.28	$317,679.60	Disclosure SEC source: 0000950170-25-028163 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,115,183 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,455,785 shares, Mr. Conroy also holds, in the aggregate, an additional 770,611 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 25, 2025 Filed Feb 26, 2025 20:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	13,180	$0.00	$0.00	Disclosure SEC source: 0000950170-25-028163 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,121,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 24, 2025 Filed Feb 26, 2025 20:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantRestricted Stock Units · Derivative	111,146	$0.00	$0.00	Disclosure SEC source: 0000950170-25-028163 · ownership.xml · derivative · entry 10 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,146 Underlying: Common Stock · 111,146 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 27, 2026. F5 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 27, 2026. Read SEC document
February 20, 2025 Filed Feb 21, 2025 16:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Tax withholdingCommon Stock	21,140	$50.48	$1,067,147.20	Disclosure SEC source: 0000950170-25-024896 · ownership.xml · nonDerivative · entry 4 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,108,198 F4 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance stock units. F5 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,448,800 shares, Mr. Conroy also holds, in the aggregate, an additional 672,645 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 20, 2025 Filed Feb 21, 2025 16:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	48,044	$0.00	$0.00	Disclosure SEC source: 0000950170-25-024896 · ownership.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,129,338 F3 · shares: Represents shares of common stock received upon settlement of a performance share unit award. Read SEC document
February 19, 2025 Filed Feb 21, 2025 16:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	10,374	$0.00	$0.00	Disclosure SEC source: 0000950170-25-024896 · ownership.xml · derivative · entry 12 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F7 · derivative.exercise_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. F7 · derivative.expiration_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. Read SEC document
February 19, 2025 Filed Feb 21, 2025 16:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Tax withholdingCommon Stock	3,271	$49.63	$162,339.73	Disclosure SEC source: 0000950170-25-024896 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,081,294 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document
February 19, 2025 Filed Feb 21, 2025 16:30 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	10,374	$0.00	$0.00	Disclosure SEC source: 0000950170-25-024896 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,084,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
November 13, 2024 Filed Nov 13, 2024 12:56 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	PurchaseCommon Stock	19,500	$51.35	$1,001,325.00	Disclosure SEC source: 0000950170-24-126119 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,191 F1 · shares: Kevin Conroy purchased in the open market 19,500 shares of Exact Sciences Corp. Common Stock at a price per share of $51.35, representing $1,001,325 worth of shares. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,414,311 shares, Mr. Conroy also holds, in the aggregate, an additional 683,018 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
May 22, 2024 Filed May 24, 2024 20:11 UTC	ALIGN TECHNOLOGY INC ALGN · Entity 3488	GrantRestricted Stock Units · Derivative	1,148	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-24-014460 · form4-05242024_080508.xml · derivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,148 Underlying: Common Stock · 1,148 shares Expires not disclosed F1 · derivative.exercise_price: Represents par value of ALGN common stock. F3 · derivative.exercise_date: 100% of the RSUs granted on May 22, 2024 will become vested on the earlier of (i) May 22, 2025 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. F3 · derivative.expiration_date: 100% of the RSUs granted on May 22, 2024 will become vested on the earlier of (i) May 22, 2025 or (ii) the date of the next annual meeting of stockholders. Shares will be delivered to the Reporting Person on such vesting date assuming the continued service of the Reporting Person on such vesting date. Read SEC document
May 22, 2024 Filed May 24, 2024 20:11 UTC	ALIGN TECHNOLOGY INC ALGN · Entity 3488	Exercise / conversionRestricted Stock Units · Derivative	660	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-24-014460 · form4-05242024_080508.xml · derivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock units (RSUs) granted on December 5, 2023 became vested and exercisable on May 22, 2024 and shares were delivered to the Reporting Person. F2 · derivative.expiration_date: 100% of the restricted stock units (RSUs) granted on December 5, 2023 became vested and exercisable on May 22, 2024 and shares were delivered to the Reporting Person. Read SEC document
May 22, 2024 Filed May 24, 2024 20:11 UTC	ALIGN TECHNOLOGY INC ALGN · Entity 3488	Exercise / conversionCommon Stock	660	$0.00	$0.00	Disclosure SEC source: 0001415889-24-014460 · form4-05242024_080508.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2024 Filed Apr 29, 2025 16:10 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GiftCommon Stock	74,599	$0.00	$0.00	Disclosure SEC source: 0000950170-25-060126 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,944 F1 · balance_after: In addition to the shares of Common Stock reported on this Form 5, which total 1,054,875 shares, Mr. Conroy also held, in the aggregate, an additional 683,019 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
May 01, 2024 Filed May 2, 2024 19:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	1,155	$60.15	$69,473.25	Disclosure SEC source: 0000950170-24-052390 · ownership.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,156,191 F4 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,394,770 shares, Mr. Conroy also holds, in the aggregate, an additional 683,018 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
April 30, 2024 Filed May 2, 2024 19:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	708	$30.02	$21,254.16	Disclosure SEC source: 0000950170-24-052390 · ownership.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,157,346 F3 · shares: Represents shares of common stock purchased through Employee Stock Purchase Plan. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,394,770 shares, Mr. Conroy also holds, in the aggregate, an additional 683,018 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
April 30, 2024 Filed May 2, 2024 19:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	2,489	$0.00	$0.00	Disclosure SEC source: 0000950170-24-052390 · ownership.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,156,638 F1 · shares: Represents additional shares of common stock received upon settlement of a performance share unit award on April 30, 2024. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,394,770 shares, Mr. Conroy also holds, in the aggregate, an additional 683,018 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
March 01, 2024 Filed Mar 4, 2024 20:38 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	8,271	$59.32	$490,635.72	Disclosure SEC source: 0001209191-24-004236 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,299,496 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,392,609 shares, Mr. Conroy also holds, in the aggregate, an additional 683,018 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 29, 2024 Filed Mar 4, 2024 20:38 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	18,143	$0.00	$0.00	Disclosure SEC source: 0001209191-24-004236 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,429 Underlying: Common Stock · 18,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 29, 2024. The restricted stock units vest in four equal annual installments from the grant date. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 29, 2024. The restricted stock units vest in four equal annual installments from the grant date. Read SEC document
February 29, 2024 Filed Mar 4, 2024 20:38 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	18,143	$0.00	$0.00	Disclosure SEC source: 0001209191-24-004236 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,307,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 27, 2024 Filed Feb 28, 2024 19:35 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	6,263	$56.89	$356,302.07	Disclosure SEC source: 0001209191-24-004078 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,289,624 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,382,737 shares, Mr. Conroy also holds, in the aggregate, an additional 701,161 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:35 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantRestricted Stock Units · Derivative	88,671	$0.00	$0.00	Disclosure SEC source: 0001209191-24-004078 · doc4.xml · derivative · entry 8 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,671 Underlying: Common Stock · 88,671 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 28, 2025. F6 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 28, 2025. Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:35 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	13,181	$0.00	$0.00	Disclosure SEC source: 0001209191-24-004078 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,361 Underlying: Common Stock · 13,181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 26, 2024. The restricted stock units vest in four equal annual installments from the grant date. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 26, 2024. The restricted stock units vest in four equal annual installments from the grant date. Read SEC document
February 26, 2024 Filed Feb 28, 2024 19:35 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	13,181	$0.00	$0.00	Disclosure SEC source: 0001209191-24-004078 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,295,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 23, 2024 Filed Feb 26, 2024 17:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionStock Option (right to buy) · Derivative	102,837	$0.00 Strike: $13.96	$0.00	Disclosure SEC source: 0001209191-24-003944 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,837 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Mr. Conroy was awarded 102,837 stock options on Feb. 24, 2014. These stock options were not exercised during the 10-year term of the award. Under the terms of the options, they were automatically exercised on the day preceding the expiration date of the options, and 61,560 shares were withheld from Mr. Conroy to pay the exercise price and taxes due upon exercise of the options. As a result, Mr. Conroy increased his holdings of Exact Sciences shares by 41,277 shares or approximately 3%. Read SEC document
February 23, 2024 Filed Feb 26, 2024 17:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Tax withholdingCommon Stock	61,560	$57.53	$3,541,546.80	Disclosure SEC source: 0001209191-24-003944 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,282,706 F1 · kind: Mr. Conroy was awarded 102,837 stock options on Feb. 24, 2014. These stock options were not exercised during the 10-year term of the award. Under the terms of the options, they were automatically exercised on the day preceding the expiration date of the options, and 61,560 shares were withheld from Mr. Conroy to pay the exercise price and taxes due upon exercise of the options. As a result, Mr. Conroy increased his holdings of Exact Sciences shares by 41,277 shares or approximately 3%. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,375,819 shares, Mr. Conroy also holds, in the aggregate, an additional 625,670 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 23, 2024 Filed Feb 26, 2024 17:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	102,837	$13.96	$1,435,604.52	Disclosure SEC source: 0001209191-24-003944 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,344,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Mr. Conroy was awarded 102,837 stock options on Feb. 24, 2014. These stock options were not exercised during the 10-year term of the award. Under the terms of the options, they were automatically exercised on the day preceding the expiration date of the options, and 61,560 shares were withheld from Mr. Conroy to pay the exercise price and taxes due upon exercise of the options. As a result, Mr. Conroy increased his holdings of Exact Sciences shares by 41,277 shares or approximately 3%. Read SEC document
February 22, 2024 Filed Feb 23, 2024 19:59 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	11,565	$59.78	$691,355.70	Disclosure SEC source: 0001209191-24-003918 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,241,429 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,334,542 shares, Mr. Conroy also holds, in the aggregate, an additional 728,507 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 21, 2024 Filed Feb 22, 2024 19:37 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	4,975	$61.50	$305,962.50	Disclosure SEC source: 0001209191-24-003867 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,229,756 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,322,869 shares, Mr. Conroy also holds, in the aggregate, an additional 728,507 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 21, 2024 Filed Feb 23, 2024 19:59 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	23,238	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003918 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,252,994 F1 · shares: Represents shares of common stock received upon settlement of a performance share unit award on February 21, 2024. Read SEC document
February 20, 2024 Filed Feb 22, 2024 19:37 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	10,374	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003867 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. Read SEC document
February 20, 2024 Filed Feb 22, 2024 19:37 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	10,374	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003867 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,234,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 15, 2024 Filed Feb 16, 2024 18:22 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	14,791	$61.43	$908,611.13	Disclosure SEC source: 0001209191-24-003463 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,224,357 F3 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 14, 2024. F4 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,317,146 shares, Mr. Conroy also holds, in the aggregate, an additional 738,881 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 14, 2024 Filed Feb 16, 2024 18:22 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	31,133	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003463 · doc4.xml · derivative · entry 8 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award that fully vested on February 14, 2024. F6 · derivative.expiration_date: Represents a restricted stock unit award that fully vested on February 14, 2024. Read SEC document
February 14, 2024 Filed Feb 16, 2024 18:22 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	31,133	$0.00	$0.00	Disclosure SEC source: 0001209191-24-003463 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,239,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
December 05, 2023 Filed Dec 7, 2023 22:23 UTC	ALIGN TECHNOLOGY INC ALGN · Entity 3488	GrantRestricted Stock Unit · Derivative	660	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-23-057749 · doc4.xml · derivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660 Underlying: Common Stock · 660 shares Expires not disclosed F1 · derivative.exercise_price: Represents par value of ALGN common stock. F2 · derivative.exercise_date: 100% of the restricted stock unit granted on December 5, 2023 will become vested on the earlier of (i) May 22, 2024 or (ii) the date of the 2024 annual meeting of stockholders. Shares will be delivered to reporting person on the vest date. F2 · derivative.expiration_date: 100% of the restricted stock unit granted on December 5, 2023 will become vested on the earlier of (i) May 22, 2024 or (ii) the date of the 2024 annual meeting of stockholders. Shares will be delivered to reporting person on the vest date. Read SEC document
May 01, 2023 Filed Feb 16, 2024 18:22 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	709	$30.02	$21,284.18	Disclosure SEC source: 0001209191-24-003463 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,208,015 F1 · shares: Represents shares of common stock purchased through Employee Stock Purchase Plan. Read SEC document
March 06, 2023 Filed Mar 9, 2023 01:05 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	GrantStock Option (right to buy) · Derivative	23,329	$0.00 Strike: $8.46	$0.00	Disclosure SEC source: 0001062993-23-006332 · form4.xml · derivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,329 Underlying: Common Stock · 23,329 shares Expires 2033-03-06 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates. Read SEC document
March 06, 2023 Filed Mar 9, 2023 01:05 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	GrantCommon Stock	14,775	$0.00	$0.00	Disclosure SEC source: 0001062993-23-006332 · form4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,968 Read SEC document
February 28, 2023 Filed Mar 1, 2023 17:15 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	10,416	$61.12	$636,625.92	Disclosure SEC source: 0001209191-23-014239 · doc4.xml · nonDerivative · entry 3 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,207,306 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 27, 2023. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,299,620 shares, Mr. Conroy also holds, in the aggregate, an additional 770,013 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 27, 2023 Filed Mar 1, 2023 17:15 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	9,312	$0.00	$0.00	Disclosure SEC source: 0001209191-23-014239 · doc4.xml · derivative · entry 9 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 27, 2023. The restricted stock units vested in four equal annual installments beginning on February 26, 2020. F6 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 27, 2023. The restricted stock units vested in four equal annual installments beginning on February 26, 2020. Read SEC document
February 27, 2023 Filed Mar 1, 2023 17:15 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	13,180	$0.00	$0.00	Disclosure SEC source: 0001209191-23-014239 · doc4.xml · derivative · entry 8 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,541 Underlying: Common Stock · 13,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 27, 2023. The restricted stock units vest in four equal annual installments beginning on February 25, 2023. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 27, 2023. The restricted stock units vest in four equal annual installments beginning on February 25, 2023. Read SEC document
February 27, 2023 Filed Mar 1, 2023 17:15 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	9,312	$0.00	$0.00	Disclosure SEC source: 0001209191-23-014239 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 27, 2023 Filed Mar 1, 2023 17:15 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	13,180	$0.00	$0.00	Disclosure SEC source: 0001209191-23-014239 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 24, 2023 Filed Feb 28, 2023 17:29 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantRestricted Stock Units · Derivative	72,572	$0.00	$0.00	Disclosure SEC source: 0001209191-23-013796 · doc4.xml · derivative · entry 6 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,572 Underlying: Common Stock · 72,572 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 29, 2024. F3 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 29, 2024. Read SEC document
February 22, 2023 Filed Feb 23, 2023 16:35 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	4,764	$62.72	$298,798.08	Disclosure SEC source: 0001209191-23-012207 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,195,230 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 21, 2023. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,287,544 shares, Mr. Conroy also holds, in the aggregate, an additional 719,933 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document
February 21, 2023 Filed Feb 23, 2023 16:35 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionRestricted Stock Units · Derivative	10,374	$0.00	$0.00	Disclosure SEC source: 0001209191-23-012207 · doc4.xml · derivative · entry 7 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,747 Underlying: Common Stock · 10,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award that partially vested on February 21, 2023. The restricted stock units vest in four equal annual installments beginning on February 19, 2022. F5 · derivative.expiration_date: Represents a restricted stock unit award that partially vested on February 21, 2023. The restricted stock units vest in four equal annual installments beginning on February 19, 2022. Read SEC document
February 21, 2023 Filed Feb 23, 2023 16:35 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	10,374	$0.00	$0.00	Disclosure SEC source: 0001209191-23-012207 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document
February 15, 2023 Filed Feb 16, 2023 17:05 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	14,617	$65.59	$958,729.03	Disclosure SEC source: 0001209191-23-010133 · doc4.xml · nonDerivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,189,620 F2 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain restricted stock units on February 14, 2023. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 1,281,908 shares, Mr. Conroy also holds, in the aggregate, an additional 730,308 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.